EHA 2016: Why the rapid development of new drugs poses new challenges

EHA 2016: Why the rapid development of new drugs poses new challenges

User Photo
VJHemOnc

4 years
672 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the issues associated with the rapid development of new drugs in chronic lymphocytic leukemia (CLL). One key issue is affordability and access according to Dr Stamatopoulos. The other issue is linked to the high pace of development of novel drugs concerns adverse events or late events.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Up Next Autoplay
>